BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

MGI Partners with NGeneBio to Advance Precision Medicine

This strategic partnership will enable the integration of NGeneBio's advanced diagnostic assays with MGI's high-throughput sequencing technology to acceler...

August 23, 2023 | News

CanariaBio's MAb-AR20.5 for Pancreatic Cancer Granted FDA Orphan Drug Designation

CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies for cancer, anno...

August 22, 2023 | News

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...

August 19, 2023 | News

Neurophth Begins Phase I/II Trial for Second Gene Therapy with First Patient Dosed

Neurophth is conducting a Phase I/II, multi-region, multi-center, single-arm, open-labeled, dose-finding study aimed at evaluating the safety, tole...

August 18, 2023 | News

Minghui Pharma Enrolls First Patient in Phase 3 Study for MH004 Cream in Atopic Dermatitis

The phase 3 clinical trial aims to evaluate the safety and efficacy of the investigational topical cream in a larger patient population. Leveraging the con...

August 18, 2023 | News

Parexel & Partex Unite Artificial Intelligence and Big Data to Speed Drug Discovery

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, a...

August 16, 2023 | News

Inmagene Initiates POC Study for Extended Half-Life OX40 mAb in Atopic Dermatitis

IMG-007 is a humanized IgG1 monoclonal antibody (mAb) that specifically binds to the OX40 receptor. Its Fc region has been bioengineered, resulting in...

August 16, 2023 | News

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

OnCusp Therapeutics Gets FDA Nod for Phase 1 Trial of CUSP06 in Ovarian & Solid Tumors

"We are delighted to announce the IND approval for our flagship program, CUSP06, which has demonstrated excellent anti-tumor efficacy across diverse in&nbs...

August 16, 2023 | News

Kelun-Biotech's Phase III Trial of SKB264 Meets Endpoint in Advanced TNBC

Kelun-Biotech recently held an Independent Data Monitoring Committee (IDMC) meeting to review the interim analysis data of the Phase III clinical trial of ...

August 15, 2023 | News

Asieris Reports Successful Phase III Bridging Trial for Hexvix® in Bladder Cancer Diagnosis

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

August 14, 2023 | News

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

Under the collaboration, Boostimmune will have access to WuXi Biologics' integrated discovery services and extensive expertise in antibody discovery, lead ...

August 11, 2023 | News

First Patient Dosed in Phase III Prostate Cancer Imaging Study of TLX591-CDx in China

The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...

August 11, 2023 | News

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) ha...

August 11, 2023 | News

Stay Connected